Remedy Place, the social wellness club founded in 2019 by Jonathan Leary, D.C., launched its first at-home smart NAD injection pen on Wednesday through a partnership with U.K.-based NADclinic, and the company says smart peptide pens could follow. The launch matters to the peptide therapy and research peptide industry because it tests whether consumers will self-inject wellness compounds at home — and because the company’s stated path to peptide pens depends on a possible FDA loosening of rules on injectable research peptides.
The nut graf: Remedy Place is not a peptide manufacturer or a compounding pharmacy. It is a brick-and-mortar wellness brand extending its most-booked injectable into a take-home device, and its peptide ambitions are stated hopes rather than launched products. For clinics, telehealth operators and suppliers watching the consumer injectable market, the episode is a signal about packaging formats and distribution routes — not evidence that any peptide is approved for at-home use.
What Remedy Place actually launched
According to Glossy, the smart NAD pen is Remedy Place’s first product of this kind and was developed with NADclinic, described as a U.K.-based, NAD-focused wellness company specializing in pharmaceutical-grade manufacturing. Each pen lasts 30 days and retails for $500, with a price break for larger orders, and is designed to be used several times per week with a new needle attached for each dose.
NAD — nicotinamide adenine dinucleotide — is a co-enzyme that naturally occurs in every human cell and begins to diminish with age, according to the report. Dr. Leary told Glossy that his clients purchase NAD drips and shots, and now the at-home pen, to boost energy, sleep, skin health and injury recovery by powering mitochondria within cells. Those are attributed client-use rationales, not established clinical outcomes; the article cites no trial data for the at-home pen.
The company promoted the new pen through social media and an email blast on Wednesday. Remedy Place does not invest in advertising and markets its offerings only through email blasts and social media posts, relying primarily on word-of-mouth, according to the report.
The prescription question at the center of the story
The most consequential claim in the reporting is regulatory. Dr. Leary told Glossy that because the new pens ship from NADclinic in the U.K., consumers can access them without a prescription, whereas NAD shots or at-home shots distributed through a U.S. compounding pharmacy would require a prescription from a medical professional.
That is a single-source, attributed claim. The article provides no regulatory or legal analysis, and it does not address whether U.S. import rules or enforcement could still apply to a product shipped from abroad. Readers should treat the prescription-free framing as the company’s characterization, not as a settled legal position. For context, U.S. compounding pharmacies operate under specific legal conditions, and compounded drugs are not FDA-approved as compounded products; the applicable rules depend on jurisdiction and product circumstances.
This distinction matters for peptide therapy clinics and telemedicine platforms, which generally operate inside prescription and medical-supervision frameworks. A consumer product sold through a U.K. wellness manufacturer and a prescription-only compounded preparation distributed stateside are different regulatory categories, even when the active ingredient carries the same name.
Key numbers behind the launch
| Item | Figure | Source / status |
|---|---|---|
| Retail price per smart NAD pen | $500 | Glossy report; price break for larger orders |
| Pen duration | 30 days | Glossy report |
| Intended use frequency | Several times per week, new needle per dose | Glossy report |
| Years NAD has been Remedy Place’s most-booked IV and shot | Over seven years | Dr. Leary, attributed |
| Remedy Place clubs | 3 (West Hollywood 2019; New York 2022; Boston 2025) | Glossy report |
| Early order markets cited | Los Angeles, New York, Denver, South Florida, Santa Fe | Dr. Leary, attributed |
No unit sales, revenue figures or conversion data were disclosed. The order-market list is an attributed observation from the founder, not audited sales data, and the article does not quantify demand.
Why the peptide pen plan is a forecast, not a launch
Dr. Leary hopes to roll out peptide pens and vitamin pens next, naming vitamin D and the “wolverine peptide blend” BPC-157 and TB-500 as examples. The report attributes that ambition partly to the potential of the FDA loosening regulation on injectable research peptides.
That is a conditional, future-oriented statement. No FDA action, proposal or timeline is cited, and the plan could proceed differently or stall depending on regulatory developments. BPC-157 and TB-500 are research peptides; a research-use designation does not establish sterility, safety or authorization for human administration, and neither compound should be described as an approved treatment. Any consumer-facing injectable peptide product would raise prescription, compounding and medical-supervision questions that the current reporting does not resolve.
Dr. Leary also said Remedy Place has had “crazy success” with its peptide rollout, which began at its West Hollywood location five years ago, and that demand for a peptide pen “would be astronomically high.” Both are unquantified founder claims. Industry observers note that club-level popularity of peptide injections does not by itself demonstrate demand for a take-home device, and no pre-order or market-sizing data was provided.
What this signals for peptide therapy clinics and suppliers
The launch is a packaging and channel story as much as a wellness story. Moving an injectable from a clinic drip or shot to a multi-dose pen shifts attention to container and device quality: pen housings, cartridge and vial formats, needle supply, labeling and instructions for use. For suppliers and clinics evaluating similar formats, the relevant questions are compatibility between the formulation and the device, stability across the stated 30-day use period, and documentation of batch-level quality.
Quality expectations do not disappear when a product is sold as a wellness item. A certificate of analysis reports specified analytical results for a material or batch; it does not independently establish clinical safety, efficacy, sterility for a particular use, regulatory approval, or suitability for administration to humans. Buyers comparing suppliers should confirm identity, purity method, impurities, storage requirements and traceability rather than relying on a headline purity figure alone.
For clinics, the operational lesson is narrower than the marketing. Remedy Place frames the pens as extensions of its brick-and-mortar business — Dr. Leary said his main focus will remain the physical clubs — and says future rollouts will be based on top performers in the clubs, similar to NAD. That is a merchandising logic peptide clinics can recognize: identify the injectables clients already rebook, then address the friction points. The only complaints Dr. Leary cited about NAD were cost and difficulty maintaining the routine while traveling or busy at home.
Supply-chain watchers should also note what the story does not say. It does not disclose where the NAD is manufactured, how the pens are filled, what stability data support the 30-day window, or how shipments are temperature-controlled. Those gaps are exactly where clinic procurement teams and research peptide buyers typically concentrate due diligence. 多肽供应链资源网 as a provider in the industry domain tracks these sourcing and documentation questions across peptide API and finished-format supply.
For readers who follow the sector closely, peptidescm and related industry resources are useful for mapping how API sourcing, fill-finish formats and cross-border distribution fit together. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
What to watch next
- Whether Remedy Place discloses unit sales or reorder rates for the NAD pen, which would test the self-injection demand thesis.
- Any FDA action on injectable research peptides, since the peptide pen plan is explicitly tied to that possibility.
- Whether a peptide pen launch, if it happens, is positioned as a prescription product, a compounded preparation or a wellness item shipped from abroad.
- Device and container details — pen format, cartridge or vial, needle supply and stability data — that would let clinics and suppliers assess comparability.
The evidence so far supports a modest conclusion: a wellness club has launched a $500, 30-day at-home NAD pen and says it hopes to add peptide and vitamin pens. Claims about prescription-free access, “astronomically high” peptide demand and clinical benefits remain attributed or unverified, and the regulatory path for any future peptide pen is unresolved.
Comments